drug
as of 2026-07-01Pomaglumetad
LY2140023Pomaglumetad methionil
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Denovo Biopharma LLC
14 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
14
Glutamate Reducing Interventions in Schizophrenia
NCT03321617Phase 1Completed
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
NCT01328093Phase 3Terminated
A Long-Term Study in Schizophrenia
NCT01487083Phase 3Terminated
A Long-Term, Open-Label, Study on Schizophrenia
NCT01129674Phase 2, Phase 3Terminated
A Physical Dependence Study in Schizophrenia
NCT01452919Phase 3Completed
A Study of LY2140023 in Patients With Schizophrenia
NCT01307800Phase 3Terminated
A Study in Schizophrenic Patients
NCT01125358Phase 2Terminated
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
NCT01606436Phase 1Completed
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
NCT01052103Phase 2Completed
A Study in Schizophrenia Patients
NCT01086748Phase 2Completed
A Study of Safety and Tolerability in Subjects With Schizophrenia
NCT01354353Phase 1Completed
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
NCT00845026Phase 2Completed
A Study for Patients With Schizophrenia
NCT00520923Phase 2Completed
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
NCT00149292Phase 2Completed
KOLs & investigators
2
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication
KOL
Scott Small, MD
personKOL score —